“The Report, “Small interfering RNA (siRNA) Therapeutics- Competitive Landscape, Technology and Pipeline Insights, 2015” depicts the current pipeline scenario of siRNA therapies under development. Many targets which were difficult to reach by traditional small-molecule and protein have been identified by therapeutics based on RNA interference (RNAi). RNA interference (RNAi), a process in recovery Phase, is still keeping the expectations of the many mid Pharma companies at a higher end with blockbuster deals and adequate delivery technologies.
This report analysis the current frontrunners in siRNA therapies with leading technologies and major acquisitions and deals seen in past 3 years. Report highlights the 16 different types of technologies that have been used lately to enhance the siRNA development in different stages of development.
There are 13+ active companies dealing with 70+ siRNA therapies. Mostly siRNA is being studied for oncology area with 24 siRNA therapies under development by major pharma companies followed by 11 therapies for infectious diseases and 8 siRNA therapies in Ophthalmology. Currently 28 siRNA are in clinical stage of development with many mid-stage products.
”
“Table 1: siRNA Technology with delivery methods, 2015
Table 2: siRNA therapeutics collaboration and deal value, 2015
Table 3: siRNA therapeutics technology licensing and deal year, 2015
Table 4: siRNA therapeutics acquisition and deal year, 2015
Table5: Number of Products Under Development for Small interfering RNA (siRNA) Therapeutics, 2015
Table 6: Number of Products under Development by Companies, 2015
Table 7: Last Stage Products (Phase III), 2015
Table 8: Mid Stage Products (Phase II), 2015
Table 9: Early Stage Products (Phase I and IND), 2015
Table 10: Pre-Clinical and Discovery Products, 2015
Table 11: Assessment by Monotherapy Products, 2015
Table 12: Assessment by Route Of Administration, 2015
Table 13:Assessment by Stage and Route Of Administration, 2015
Table 14: Discontinued Products, 2015
Table 15: Dormant Products, 2015
Table 16: siRNA Companies involved in Therapeutics Development, 2015
“
“Figure 1: Number of collaborations with year, 2015
Figure 2: Number of products with siRNA technologies, 2015
Figure 3: Number of technology associated with the companies, 2015
Figure 4: Number of products with therapy area, 2015
Figure 5: Number of products with therapy area in different Pre-Clinical and Clinical Phases, 2015
Figure 6: Number of products with ongoing and completed clinical trials, 2015
Figure 7: Number of products in clinical trials with companies, 2015
Figure 8: Number of products with designations, 2015
Figure 9: Number of Products under Development for Small interfering RNA (siRNA) Therapeutics, 2015
Figure 10:Last Stage Products (Phase III), 2015
Figure 11: Mid Stage Products (Phase II), 2015
Figure 12:Early Stage Products (Phase I and IND), 2015
Figure 13:Pre-Clinical and Discovery Products, 2015
Figure 14: Assessment by Monotherapy Products, 2015
Figure 15: Assessment by Combination Products, 2015
Figure 16: Assessment by Route of Administration, 2015
“
